Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR

Hitomi Sakai,¹ Hidetoshi Hayashi,¹ Tsutomu Iwasa,¹ Yoshikazu Hasegawa,² Masayuki Takeda,¹ Kazuhiko Nakagawa¹

ABSTRACT
Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) that has been approved for the treatment of metastatic non-small cell lung cancer (NSCLC) positive for the secondary T790M mutation of EGFR. In a preclinical study, it also showed efficacy against leptomeningeal carcinomatosis (LMC) derived from NSCLC resistant to first-generation and second-generation EGFR-TKIs. We now report the case of a patient aged 70 years with symptomatic LMC derived from NSCLC with the T790M mutation of EGFR who showed a clinical and radiographic response to osimertinib.

INTRODUCTION
Leptomeningeal carcinomatosis (LMC) is a fatal complication of advanced cancer, the incidence of which has been increasing in association with the prolongation of survival in patients with non-small cell lung cancer (NSCLC) due to recent advances in systemic therapy.¹ Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been found to be effective in patients with LMC derived from lung adenocarcinoma positive for an activating mutation of EGFR.²⁻⁴ However, most patients who initially benefit from a first-generation EGFR-TKI eventually develop disease progression, with 50% of cases of acquired resistance due to a secondary T790M mutation of EGFR.⁵ Third-generation EGFR-TKIs has recently been developed to overcome such acquired resistance. A dose-escalation phase I study (AURA) showed that the third-generation EGFR-TKI osimertinib induced a marked clinical response (response rate of 61%) in previously treated NSCLC patients with the T790M mutation.⁶ Given its high efficacy, osimertinib is also expected to be effective against LMC derived from NSCLC positive for this mutation. We now report a case of LMC in a patient with T790M-positive NSCLC treated with osimertinib.

CASE REPORT
A Japanese woman aged 70 years with no smoking history was diagnosed with stage IV lung adenocarcinoma and brain and lumbar vertebral metastases. Given that the primary tumour was found to harbour an EGFR L858R mutation, the patient was treated with gefitinib as a first-line therapy and...
subsequently received erlotinib, the combination of pemetrexed and carboplatin, S-1, and docetaxel over the course of 4 years. She also underwent stereotactic radiosurgery for the brain metastasis four times during the treatment course. After subsequent disease progression, a rebiopsy of the primary lesion revealed the EGFR T790M mutation. Erlotinib was again administered for 8 months until disease progression in a clinical trial.

Six days after erlotinib discontinuation, the patient was urgently hospitalised as a result of severe fatigue, appetite loss and a slight headache. Her Eastern Cooperative Oncology Group performance status (PS) had deteriorated to 3 on the day of admission. MRI of the brain revealed LMC and multiple brain metastases (figure 1A, B). Progression at extracranial sites was not observed. As a seventh-line treatment, osimertinib was administered at a dose of 80 mg, resulting in relief of symptoms within a few days. MRI at 7 weeks after initiation of osimertinib showed shrinkage of the multiple nodular deposits in the brain (figure 1C, D), and treatment is currently ongoing and well tolerated.

**DISCUSSION**

The patient was diagnosed with LMC derived from NSCLC positive for the T790M mutation of EGFR and was successfully treated with osimertinib. The present case suggests that osimertinib is a potentially effective treatment for LMC associated with EGFR mutation-positive lung cancer that has developed resistance to a first-generation EGFR-TKI, and that osimertinib is a treatment option for patients with a poor PS due to complications of cancer progression.

Osimertinib was previously shown to have activity in a mouse model of LMC resistant to first-generation and second-generation EGFR-TKIs. A phase I study of the safety of osimertinib in patients with LMC derived from NSCLC resistant to prior EGFR-TKI therapy is ongoing (NCT02228369). Although little is known of the clinical efficacy of osimertinib for LMC associated with EGFR T790M-positive NSCLC, the present case supports the findings of the previous preclinical study.

Given that EGFR-TKIs induce a pronounced clinical response with an improved toxicity profile compared with chemotherapy, administration of these agents is an option for patients with a poor PS. A phase II study thus found that EGFR mutation-positive NSCLC patients with a poor PS benefited from first-line treatment with gefitinib. An early-phase trial of osimertinib revealed promising efficacy for EGFR T790M-positive NSCLC and an acceptable toxicity profile. The present case suggests that osimertinib is a feasible option for NSCLC patients with the T790M mutation whose PS is impaired due to complications of cancer progression.

Nevertheless, there is a limitation to our report. As we did not perform EGFR T790M mutational analysis for cerebrospinal fluid, there is a possibility of no T790M mutation in the central nervous system. The good penetration of osimertinib into cerebrospinal fluid might enable response even if T790M mutation was negative in the central nervous system.
In summary, we present a case of LMC associated with EGFR T790M-positive NSCLC that showed a response to osimertinib. Further studies are warranted to evaluate the efficacy of osimertinib for such patients.

Acknowledgements The authors would like to thank patient and her family.

Contributors HS and HH were responsible for clinical management of the patient, acquisition of data and drafting the manuscript. TI, YH, MT and KN were responsible for interpretation of data and critical revision of the manuscript. All authors read and approved the final version of the manuscript.

Competing interests HH has received lecture fees from AstraZeneca K.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Eli Lilly Japan K.K., Ono Pharmaceutical Co. and Taiho Pharmaceutical Co. as well as advisory fees from AstraZeneca K.K., Boehringer-Ingelheim Japan and Eli Lilly Japan K.K. KN has received lecture fees and advisory fees from Chugai Pharmaceutical Co. and Taiho Pharmaceutical Co. as well as advisory fees from AstraZeneca K.K., Boehringer-Ingelheim Japan and Eli Lilly Japan K.K. All other authors declare no potential conflicts of interest.

Patient consent Obtained.

Ethics approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and within the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patient of this study.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

1. Lee SJ, Lee JI, Nam DH, et al. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol 2013;8:185–91.
2. Wagner M, Besse B, Baileyguier C, et al. Leptomeningeal and medullary response to second-line erlotinib in lung adenocarcinoma. J Thorac Oncol 2008;3:677–9.
3. Katayama T, Shimizu J, Suda K, et al. Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. J Thorac Oncol 2009;4:1415–19.
4. Lee E, Keam B, Kim DW, et al. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol 2013;8:1069–74.
5. Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006;12:5764–9.
6. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689–99.
7. Nanjo S, Ebi H, Arai S, et al. High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells. Oncotarget 2016;7:3847–56.
8. Yang JCH, Kim DW, Kim SW, et al. Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): updated results from BLOOM, a phase I study. 2016 ASCO Annual Meeting. J Clin Oncol 2016;34:abstr 9002.
9. Inoue A, Kobayashi K, Usui K, et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009;27:1394–400.
10. Hata A, Katakami N, Yoshioka H, et al. Spatiotemporal T790M heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKIs. J Thorac Oncol 2015;10:1553–9.
11. Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res 2016;22:5130–40. Epub ahead of print.